Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Brian N. Bundy"'
Publikováno v:
Endocrinology, Diabetes & Metabolism, Vol 3, Iss 3, Pp n/a-n/a (2020)
Abstract Introduction This paper develops a methodology and defines a measure that can be used to separate subjects that received an experimental therapy into those that benefitted from those that did not in recent‐onset type 1 diabetes. Benefit me
Externí odkaz:
https://doaj.org/article/ffbf963e8f154213915011780a90afe0
Autor:
Kevan C. Herold, Anette-Gabriele Ziegler, Darrell M. Wilson, Diane K. Wherrett, John M Wentworth, Jay S. Skyler, Phillip Raskin, Andrew B. Muir, Antoinette M. Moran, Wayne V Moore, Daniel J. Moore, Sandra M. Lord, S. Alice Long, Peter S. Linsley, Ingrid M. Libman, Jeffrey P Krischer, Michael J. Haller, Carla J. Greenbaum, Peter A. Gottlieb, Robin S. Goland, Stephen E. Gitelman, Laura A. Cooney, Mark S. Anderson, Brian N. Bundy, William E. Russell
Objective Previous studies showed that inhibiting lymphocyte costimulation reduces declining beta cell function in individuals newly-diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e612bbc18c514cf7dd93b604e719af2d
https://doi.org/10.2337/figshare.22009586
https://doi.org/10.2337/figshare.22009586
Autor:
Mark A. Atkinson, Desmond A. Schatz, Michael J. Haller, Laura M. Jacobsen, Stephen E. Gitelman, Madison N. Greco, Brian N. Bundy, Todd M. Brusko, Clayton E. Mathews, Kevan C. Herold, Jeffrey P. Krischer
Publikováno v:
Diabetes Technology & Therapeutics
Several immunotherapies have demonstrated endogenous insulin preservation in recent-onset type 1 diabetes (T1D). We considered the primary results of rituximab, abatacept, teplizumab, alefacept, high-dose antithymocyte globulin (ATG), low-dose ATG, a
Publikováno v:
Diabetes Care
OBJECTIVE Insulin secretion declines rapidly after diagnosis of type 1 diabetes, followed by a slower rate of change. Previous studies have demonstrated that the C-peptide decline begins before the clinical diagnosis. Changes in insulin secretion in
Autor:
Tracey D, Graves, Robert C, Griggs, Brian N, Bundy, Joanna C, Jen, Robert W, Baloh, Michael G, Hanna, Jennifer, Lloyd
Publikováno v:
Cerebellum (London, England).
Episodic ataxia type 1 (EA1) is a rare autosomal potassium channelopathy, due to mutations in KCNA1. Patients have childhood onset of intermittent attacks of ataxia, dizziness or imbalance. In order to quantify the natural history of EA1, its effect
Autor:
Laura M Jacobsen, Brian N Bundy, Heba M Ismail, Mark Clements, Megan Warnock, Susan Geyer, Desmond A Schatz, Jay M Sosenko
Publikováno v:
The Journal of clinical endocrinology and metabolism. 107(10)
Context HbA1c from ≥ 5.7% to < 6.5% (39-46 mmol/mol) indicates prediabetes according to American Diabetes Association guidelines, yet its identification of prediabetes specific for type 1 diabetes has not been assessed. A composite glucose and C-pe
Publikováno v:
New England Journal of Medicine. 381:1879-1881
Autor:
Kevan C, Herold, Brian N, Bundy, S Alice, Long, Jeffrey A, Bluestone, Linda A, DiMeglio, Matthew J, Dufort, Stephen E, Gitelman, Peter A, Gottlieb, Jeffrey P, Krischer, Peter S, Linsley, Jennifer B, Marks, Wayne, Moore, Antoinette, Moran, Henry, Rodriguez, William E, Russell, Desmond, Schatz, Jay S, Skyler, Eva, Tsalikian, Diane K, Wherrett, Anette-Gabriele, Ziegler, Carla J, Greenbaum, Stuart, Weinzimer
Publikováno v:
The New England journal of medicine, vol 381, iss 7
BackgroundType 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type
Autor:
Antoinette Moran, S. Alice Long, Susan Geyer, Megan V. Warnock, Linda A. DiMeglio, Henry Rodriguez, Jennifer B. Marks, Dorothy J. Becker, David A. Baidal, J Lori Blanchfield, Darrell M. Wilson, Peter A. Gottlieb, Stephen E. Gitelman, Desmond A. Schatz, Brian N. Bundy, Jessica L. Miller, Mark A. Atkinson, Michael J. Haller, Jay S. Skyler, Carla J. Greenbaum, Robin Goland, Jeffrey P. Krischer, Kevan C. Herold, William E. Russell
Publikováno v:
Diabetes
A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrated that low-dose anti-thymocyte globulin (ATG) (2.5 mg/kg) preserved β-cell function and reduced HbA
Autor:
Emily K, Sims, Brian N, Bundy, Kenneth, Stier, Elisavet, Serti, Noha, Lim, S Alice, Long, Susan M, Geyer, Antoinette, Moran, Carla J, Greenbaum, Carmella, Evans-Molina, Kevan C, Herold, Anette-Gabriele, Ziegler
Publikováno v:
Sci Transl Med
We analyzed the effects of a single 14-day course of teplizumab treatment on metabolic function and immune cells among participants in a previously reported randomized controlled trial of nondiabetic relatives at high risk for type 1 diabetes (T1D).